(Q40600552)

21 September 2017

title

Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with renal-cell carcinoma: clinical and laboratory effects (English)

1 reference

21 September 2017

main subject

phase I clinical trial

0 references

author name string

J Tate

1

1 reference

21 September 2017

T Olencki

2

1 reference

21 September 2017

J Finke

3

1 reference

21 September 2017

K Kottke-Marchant

4

1 reference

21 September 2017

L A Rybicki

5

1 reference

21 September 2017

R M Bukowski

6

1 reference

21 September 2017

publication date

1 May 2001

1 reference

21 September 2017

1 reference

21 September 2017

volume

12

1 reference

21 September 2017

issue

5

1 reference

21 September 2017

page(s)

655-659

1 reference

21 September 2017

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011123432765

7 January 2021

https://api.crossref.org/works/10.1023%2FA%3A1011123432765

1 reference

7 January 2021

Spontaneous regression of metastases of renal cancer: A report of two cases including the first recorded regression following irradiation of a dominant metastasis and review of the world literature

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011123432765

7 January 2021

Treatment of renal cell carcinoma with escalating doses of alpha-interferon

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011123432765

7 January 2021

Interferon-alpha and survival in renal cell cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011123432765

7 January 2021

Recombinant beta-interferon in the treatment of patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011123432765

7 January 2021

Complete response of metastatic renal cell carcinoma to low-dose interferon-gamma treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011123432765

7 January 2021

Phase II trial of low dose gamma-interferon in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011123432765

7 January 2021

Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011123432765

7 January 2021

Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011123432765

7 January 2021

Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011123432765

7 January 2021

Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011123432765

7 January 2021

The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100)

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011123432765

7 January 2021

Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011123432765

7 January 2021

Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011123432765

7 January 2021

Antitumor activity of recombinant interleukin 6 in mice

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011123432765

7 January 2021

Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011123432765

7 January 2021

Identifiers

DOI

10.1023/A:1011123432765

1 reference

21 September 2017

1 reference